Scholarlink

<p>ORC1 is a core protein governing DNA replication initiation and cell cycle regulation, exhibiting significant overexpression in multiple malignancies where it correlates with advanced disease stage and poor prognosis. It drives tumor progression through diverse mechanisms including activation of ERK/JNK and Wnt signaling pathways, inhibition of ferroptosis via SLC7A11, and promotion of epithelial-mesenchymal transition. Its expression is regulated through multiple layers including m6A modification by IGF2BP1, the XIST/miR-140-5p axis, transcription factors like ETV4, and epigenetic regulators including EZH2. ORC1 represents a promising therapeutic target, as its inhibition induces replication stress, cell cycle arrest, and enhances sensitivity to existing chemotherapeutic agents. Future research should focus on developing specific ORC1 inhibitors and exploring their synergistic potential with immunotherapy and targeted therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Origin recognition complex subunit 1 functions as an oncogenic driver and therapeutic target in cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Yixuan Ding,
  • Shiwei Cai,
  • Jinzhou Cai,
  • Zhanpeng Wang,
  • Zigui Zhu

摘要

ORC1 is a core protein governing DNA replication initiation and cell cycle regulation, exhibiting significant overexpression in multiple malignancies where it correlates with advanced disease stage and poor prognosis. It drives tumor progression through diverse mechanisms including activation of ERK/JNK and Wnt signaling pathways, inhibition of ferroptosis via SLC7A11, and promotion of epithelial-mesenchymal transition. Its expression is regulated through multiple layers including m6A modification by IGF2BP1, the XIST/miR-140-5p axis, transcription factors like ETV4, and epigenetic regulators including EZH2. ORC1 represents a promising therapeutic target, as its inhibition induces replication stress, cell cycle arrest, and enhances sensitivity to existing chemotherapeutic agents. Future research should focus on developing specific ORC1 inhibitors and exploring their synergistic potential with immunotherapy and targeted therapies.